Bethesda system

Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022

Retrieved on: 
Monday, October 10, 2022
Rx, Philips Innovation Award, Therapy, Drug development, Patient, Deutsches Museum, Starnberg, Gedeon Richter, COVID-19, Sanofi, Digital health, BioNTech, Degenerative disease, Plasma protein binding, Diagnosis, Bethesda system, Morning, Achondroplasia, Breast cancer, Prostate cancer, OTC, Vaccination, Pharmacist, Almirall, Harris Interactive, Pharmaceutical industry, Pfizer

The ranking Best pharmaceutical companies in Germany 2022 is set.

Key Points: 
  • The ranking Best pharmaceutical companies in Germany 2022 is set.
  • Janssen-Cilag, Novartis Pharma, Bayer Vital, Sanofi and Pfizer occupy spots one to five in the Pharma Trend Image & Innovation Award survey.
  • In addition, the four winners for the The Golden Tablet award were announced: BioNTech, InfectoPharm, Jenapharm and Janssen-Cilag.
  • It was part of the 23rd Pharma Trend Image & Innovation Award again this year under the patronage of the Bavarian Minister of Health Klaus Holetschek.

Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022

Retrieved on: 
Friday, September 16, 2022
Biotechnology, Pharmaceutical, Health, Starnberg, Deutsches Museum, Almirall, COVID-19, Plasma protein binding, Vaccination, Achondroplasia, Degenerative disease, BioMarin Pharmaceutical, Diagnosis, Therapy, Drug development, Patient, Breast cancer, Golden, OTC, Pharmacist, Philips Innovation Award, BioNTech, Digital health, Rx, Bethesda system, Prostate cancer, Gedeon Richter, Morning, Sanofi, Harris Interactive, Pharmaceutical industry, Pfizer

The ranking Best pharmaceutical companies in Germany 2022 is set.

Key Points: 
  • The ranking Best pharmaceutical companies in Germany 2022 is set.
  • Janssen-Cilag, Novartis Pharma, Bayer Vital, Sanofi and Pfizer occupy spots one to five in the Pharma Trend Image & Innovation Award survey.
  • In addition, the four winners for the "The Golden Tablet" award were announced: BioNTech, InfectoPharm, Jenapharm and Janssen-Cilag.
  • It was part of the 23rd Pharma Trend Image & Innovation Award - again this year under the patronage of the Bavarian Minister of Health Klaus Holetschek.

Global Cervical Dysplasia Market Research Report to 2027 - by Diagnostics Type, Treatment Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Pharmaceutical, Health, Surgery, CAGR, Market share analysis, USD, Strategic management, Investment, Customer support, Growth, Certification, Bethesda system, Use, COVID-19, Business Growth Fund, Value, R, Acquisition, Decision-making, Retail, Birth control

What are the inhibiting factors and impact of COVID-19 shaping the Global Cervical Dysplasia Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Cervical Dysplasia Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cervical Dysplasia Market?
  • What is the market share of the leading vendors in the Global Cervical Dysplasia Market?
  • What modes and strategic moves are considered suitable for entering the Global Cervical Dysplasia Market?

New testing device from March of Dimes Prematurity Research Center at Imperial College London allows for rapid detection of bacteria that identify risk for preterm birth

Retrieved on: 
Wednesday, October 13, 2021
University, Bethesda system, Gold, Resolution (mass spectrometry), HIV, NHS, Vagina, IVF, Technology, Reproduction, Twitter, Inflammation, Digestion, College, COVID-19, HPV, Imperial, Computational Biology Department, Nature Communications, Instagram, Woman, United Kingdom, Bacterial vaginosis, Kate, Infant, Medicine, Solution, Student, Bacteria, Reuters, Engineering, Multimedia, Metabolism, Hospital, Pregnancy, Death, Family, Color, Knowledge, Preterm birth, Cervical cerclage, View, Facebook, Risk, Virology, Department, Times Higher Education, Diagnosis, Industry, Education, Health, Institute, Cervical cancer, CEO, Patient, Science, Miscarriage, Research, Imperial College London, Birth control

ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.

Key Points: 
  • ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.
  • In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth.
  • March of Dimes, the infant and maternal health leader, is dedicated to advancing knowledge and solutions for preterm birth.
  • At Imperial College London, research is highlighting the important role of the reproductive tract microbiome in shaping preterm birth risk and other pregnancy outcomes.

New testing device from March of Dimes Prematurity Research Center at Imperial College London allows for rapid detection of bacteria that identify risk for preterm birth

Retrieved on: 
Wednesday, October 13, 2021
Twitter, Reproduction, Facebook, Inflammation, Technology, Digestion, Risk, Reuters, Virology, College, Pregnancy, Department, Engineering, COVID-19, University, HPV, Bethesda system, Gold, Times Higher Education, Imperial, Diagnosis, Resolution (mass spectrometry), HIV, Metabolism, Industry, Education, Nature Communications, Computational Biology Department, Instagram, Health, Hospital, Institute, Woman, United Kingdom, Bacterial vaginosis, NHS, Death, Family, Cervical cancer, Kate, Color, Infant, Knowledge, CEO, Medicine, Preterm birth, Solution, Vagina, Patient, Science, Student, Miscarriage, Research, IVF, Cervical cerclage, Bacteria, Imperial College London, Birth control

ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth. A study, published in Nature Communications, finds that the device can rapidly and accurately detect changes in vaginal bacteria and corresponding immune responses in pregnant women, which are associated with increased risk of preterm birth. This cost-effective test could facilitate faster clinical decision making and help improve targeted treatment strategies during pregnancy.

Key Points: 
  • ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.
  • In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth.
  • March of Dimes, the infant and maternal health leader, is dedicated to advancing knowledge and solutions for preterm birth.
  • At Imperial College London, research is highlighting the important role of the reproductive tract microbiome in shaping preterm birth risk and other pregnancy outcomes.

Eurecon Verlag: Pharma Trend Awards Best Pharmaceutical Companies and the Most Innovative Products 2021

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Rx, Anticalin, Golden, Johnson & Johnson, Avenio, OTC, Lilly, Gilead Sciences, Bristol Myers Squibb, Bethesda system, BioNTech, Mycosis fungoides, Industry, Prostate cancer, Deutsches Museum, Acid erosion, Plasma protein binding, Orphan, COVID-19, Roche Diagnostics, Diagnosis, Philips Innovation Award, Pharmaceutical industry

In addition to the company's research activity, a large product pipeline with many innovations is decisive for the award, as well as the quality of the products.

Key Points: 
  • In addition to the company's research activity, a large product pipeline with many innovations is decisive for the award, as well as the quality of the products.
  • The ranking "Best Pharmaceutical Companies Germany 2021" was also published: Roche Pharma, Lilly, Bristol-Myers Squibb, Novartis Pharma and Amgen occupy places one to five in the Pharma Trend Image & Innovation Award survey.
  • Thirteen other winners were able to enjoy the award "Most Innovative Product".
  • The app MyIUS from Jenapharm, which accompanies users of intrauterine systems, was chosen in the Digital Health Applications category.

Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021

Retrieved on: 
Thursday, September 16, 2021
PD-L1, Immunotherapy, Thyroid cancer, 2021 Essex County Council election, Genetic counseling, European Society for Medical Oncology, Cholangiocarcinoma, Patient, TMB, ESMO, GTH, Sarcoma, Bethesda system, EPHA3, Genomics, Stromal cell, Disease, Trauma, Neoplasm, NASDAQ, Solution, Abstract (summary), KRAS, BSRTC, FNA, GLOBE, SMARCA2, Lung cancer, Cancer, Diagnosis, Research, SMARCA4, Oncology, Health, Congress, Medical imaging

The research adopted Genetrons proprietary technology such as the One-Step Seq Method, and core products such as Onco PanScanand its thyroid cancer full-cycle gene test.

Key Points: 
  • The research adopted Genetrons proprietary technology such as the One-Step Seq Method, and core products such as Onco PanScanand its thyroid cancer full-cycle gene test.
  • These findings were from both multi-cancer studies and high-risk single cancer studies, which covered lung cancer, thyroid cancer, cholangiocarcinoma, and central nervous system cancers.
  • Genetron Health's research findings provide new strategies for precise diagnosis and treatment of the Chinese population.
  • For these patients, Genetron Health has developed a full-cycle gene test for thyroid cancer that is based on the One-Step Seq Method.

HealthLynked Corp. Announces the Addition of Sabrina Katz as Multimedia Executive Producer and Spokesperson

Retrieved on: 
Thursday, July 29, 2021
Human development, Endocrine system, Menopause, Clinical medicine, Endocrinology, Hormone replacement therapy, Breast cancer, LinkedIn

Miss Katz will oversee creating a wide range of educational, informative, and unique video content for HealthLynked.

Key Points: 
  • Miss Katz will oversee creating a wide range of educational, informative, and unique video content for HealthLynked.
  • News segments will feature common health issues starting with women's healthcare covering menopause, hormone replacement therapies, breast cancer, cervical dysplasia and more.
  • "We are excited to have Sabrina join HealthLynked as our multimedia producer and company spokesperson.
  • For additional information about HealthLynked Corp., please visit www.healthlynked.com and connect with HealthLynked on Twitter, Facebook, and LinkedIn.

BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities

Retrieved on: 
Wednesday, July 22, 2020
Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Papillomavirus, Gynaecological cancer, RTT, Vaccines, Human papillomavirus infection, Genotyping, Bethesda system, Cervical screening

The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.

Key Points: 
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • BD Onclarity HPV Assay has FDA approval for use in vaccinated women.
  • Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with NILM cytology.
  • Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, >/=21years of age, with ASC-US or LSIL cytology.

C2 CryoBalloon™ Ablation System Validated As Effective, Durable And Well-Tolerated By Patients

Retrieved on: 
Wednesday, June 6, 2018
Medicine, Medical terminology, Interventional radiology, Barrett's esophagus, Surgical oncology, Dysplasia, Ablation, Bethesda system, Radiofrequency ablation

In a prospective clinical trial, consecutive BE patients with confirmed neoplasia (low-grade dysplasia, high-grade dysplasia, and/or intramucosal adenocarcinoma) were treated with the C2 CryoBalloon.

Key Points: 
  • In a prospective clinical trial, consecutive BE patients with confirmed neoplasia (low-grade dysplasia, high-grade dysplasia, and/or intramucosal adenocarcinoma) were treated with the C2 CryoBalloon.
  • "Early results from the study suggest that the [C2 CryoBalloon ablation] of ESCN is safe, well-tolerated and highly effective."
  • European clinicians conducted a multicenter, non-randomized cohort study that compared the tolerability of patients treated for Barrett's esophagus after both C2 CryoBalloon ablation and radio frequency ablation.
  • Patients were transfused an average of 1.75 units/month one year prior to C2 CryoBalloon ablation and an average of 0.31 units/month up to 6 months following C2 CryoBalloon ablation.